ChromaDex (CDXC) Analysts See $-0.04 EPS; Owens & Minor (OMI)’s Sentiment Is 1

April 22, 2018 - By Adrian Mccoy

Owens & Minor, Inc. (NYSE:OMI) Logo

Analysts expect ChromaDex Corporation (NASDAQ:CDXC) to report $-0.04 EPS on May, 10.They anticipate $0.01 EPS change or 20.00% from last quarter’s $-0.05 EPS. After having $-0.17 EPS previously, ChromaDex Corporation’s analysts see -76.47% EPS growth. The stock decreased 1.66% or $0.07 during the last trading session, reaching $4.15. About 141,974 shares traded. ChromaDex Corporation (NASDAQ:CDXC) has risen 63.20% since April 22, 2017 and is uptrending. It has outperformed by 51.65% the S&P500.

Owens & Minor Inc (OMI) investors sentiment decreased to 1 in Q4 2017. It’s down -0.47, from 1.47 in 2017Q3. The ratio turned negative, as 115 funds opened new or increased stock positions, while 115 reduced and sold equity positions in Owens & Minor Inc. The funds in our database now have: 58.40 million shares, up from 57.73 million shares in 2017Q3. Also, the number of funds holding Owens & Minor Inc in top ten stock positions was flat from 1 to 1 for the same number . Sold All: 58 Reduced: 57 Increased: 77 New Position: 38.

ChromaDex Corporation, a natural products company, discovers, acquires, develops, and commercializes patented and proprietary ingredient technologies. The company has market cap of $227.57 million. The firm offers bulk raw materials for use in dietary supplements, food, beverages, and cosmetic products; Nicotinamide riboside , a vitamin found naturally in milk for enhancing cardiovascular health, glucose levels, cognitive function, and anti-aging effects; Pterostilbene (pTeroPure), a polyphenol and antioxidant used in health related fields; and Immulina, a spirulina extract and compound, which is used for improving human immune function, as well as developing Pterostilbene and caffeine co-crystal ingredients, and anthocyanins ingredients. It currently has negative earnings. It also provides reference standards, materials, and kits to conduct quality control of raw materials and consumer products; and fine chemicals and phytochemicals for research and new product development applications.

Analysts await Owens & Minor, Inc. (NYSE:OMI) to report earnings on May, 1. They expect $0.47 earnings per share, up 14.63% or $0.06 from last year’s $0.41 per share. OMI’s profit will be $29.06M for 8.04 P/E if the $0.47 EPS becomes a reality. After $0.35 actual earnings per share reported by Owens & Minor, Inc. for the previous quarter, Wall Street now forecasts 34.29% EPS growth.

The stock decreased 2.20% or $0.34 during the last trading session, reaching $15.11. About 803,873 shares traded. Owens & Minor, Inc. (OMI) has declined 56.18% since April 22, 2017 and is downtrending. It has underperformed by 67.73% the S&P500.

Adirondack Research & Management Inc. holds 2.17% of its portfolio in Owens & Minor, Inc. for 292,220 shares. Gilman Hill Asset Management Llc owns 188,466 shares or 1.45% of their US portfolio. Moreover, Smith Graham & Co. Investment Advisors Lp has 0.79% invested in the company for 443,814 shares. The Ohio-based Opus Capital Group Llc has invested 0.65% in the stock. Brandes Investment Partners Lp, a California-based fund reported 1.45 million shares.

Owens & Minor, Inc. (NYSE:OMI) Institutional Positions Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:

Recent Posts